|Articles|January 18, 2002

CDER News 1/7/02

Author(s)BioPharm International Editors

Drug approvals for 2001 and new approvals

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Subscribe Now!

Related Content

Image Credit: ©Teeraphon; navintar – Stock.Adobe.com

How Mitigation and Maintenance Protect Against Future Risk

BySusan Haigney

December 8th 2025

3d rendering of Bispecific antibodies or BsAbs have two distinct binding domains that can bind to two antigens or two epitopes of the same antigen simultaneously. |Image credit: © Love Employee - © Love Employee - stock.adobe.com

Roche Drives Industry Shift With Three-Year Lymphoma Survival Data

ByFeliza Mirasol

December 8th 2025

T-Cells Work to Fight Cancer, Immunotherapy, CAR T-cell therapy, 3d rendering | Image credit: © Design Cells - © Design Cells - stock.adobe.com

New Lymphoma Indication for CAR T-Cell Therapy Shapes Pipeline

ByFeliza Mirasol

December 5th 2025

Parkinson's disease. 3D illustration showing neurons containing Lewy bodies small red spheres which are deposits of proteins (alpha-synuclein) accumulated in the brain cells. | Image credit: © Lars Neumann - © Lars Neumann - stock.abode.com

Neurimmune and AstraZeneca Expand Efforts to Accelerate Fibril-Depleting Therapies

ByFeliza Mirasol

December 4th 2025

small interfering RNA bound to a messenger RNA, cartoon model with semi-transparent surface. siRNAs are synthetic RNA interference tools used for inducing temporary reduction of mRNA expression. | Image credit: © petarg - © petarg - stock.adobe.com

Emerging siRNA Platform Offers New Metabolic Disorder Therapies

ByFeliza Mirasol

December 3rd 2025

CDER News 1/7/02

Newsletter

Related Content

How Mitigation and Maintenance Protect Against Future Risk

Roche Drives Industry Shift With Three-Year Lymphoma Survival Data

New Lymphoma Indication for CAR T-Cell Therapy Shapes Pipeline

Neurimmune and AstraZeneca Expand Efforts to Accelerate Fibril-Depleting Therapies

Emerging siRNA Platform Offers New Metabolic Disorder Therapies

Trending on BioPharm International

Neurimmune and AstraZeneca Expand Efforts to Accelerate Fibril-Depleting Therapies

Roche Drives Industry Shift With Three-Year Lymphoma Survival Data

New Lymphoma Indication for CAR T-Cell Therapy Shapes Pipeline

How Mitigation and Maintenance Protect Against Future Risk

Top 10 BioPharm International Articles of 2025